Total Payments
$7,484
2024 Payments
$895.29
Companies
62
Transactions
260
Medicare Patients
5,805
Medicare Billing
$959,490
Payment Breakdown by Category
Food & Beverage$4,849 (64.8%)
Consulting$1,665 (22.2%)
Research$796.35 (10.6%)
Education$173.72 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,849 | 252 | 64.8% |
| Consulting Fee | $1,665 | 1 | 22.2% |
| Unspecified | $796.35 | 1 | 10.6% |
| Education | $173.72 | 6 | 2.3% |
Payments by Type
General
$6,688
259 transactions
Research
$796.35
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,055 | 19 | $0 (2024) |
| Eli Lilly and Company | $796.35 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $468.59 | 22 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $387.30 | 40 | $0 (2024) |
| Astellas Pharma US Inc | $338.30 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $334.42 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $208.10 | 9 | $0 (2024) |
| PFIZER INC. | $201.70 | 12 | $0 (2024) |
| GENZYME CORPORATION | $143.37 | 6 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $138.94 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $895.29 | 36 | PFIZER INC. ($131.78) |
| 2023 | $978.59 | 40 | Merck Sharp & Dohme LLC ($103.34) |
| 2022 | $836.48 | 33 | Astellas Pharma US Inc ($128.50) |
| 2021 | $2,712 | 16 | AstraZeneca Pharmaceuticals LP ($1,701) |
| 2020 | $200.41 | 11 | Janssen Biotech, Inc. ($77.25) |
| 2019 | $762.69 | 52 | Novartis Pharmaceuticals Corporation ($122.15) |
| 2018 | $568.56 | 31 | Janssen Biotech, Inc. ($102.78) |
| 2017 | $530.74 | 41 | Novartis Pharmaceuticals Corporation ($104.58) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $30.07 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.29 | General |
| 11/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $43.39 | General |
| Category: Oncology | ||||||
| 10/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.36 | General |
| Category: Hematology/Oncology | ||||||
| 09/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/06/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $1.59 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Oncology | ||||||
| 08/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Oncology | ||||||
| 08/07/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.11 | General |
| 07/08/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Oncology | ||||||
| 06/17/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $24.81 | General |
| Category: Oncology | ||||||
| 05/07/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $35.13 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $34.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $796.35 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,170 | 40,098 | $521,953 | $119,840 |
| 2022 | 33 | 1,513 | 38,587 | $619,081 | $159,281 |
| 2021 | 35 | 1,600 | 20,039 | $1.1M | $348,187 |
| 2020 | 36 | 1,522 | 33,742 | $888,127 | $332,183 |
Total Patients
5,805
Total Services
132,466
Medicare Billing
$959,490
Procedure Codes
136
All Medicare Procedures & Services
136 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 248 | $92,047 | $21,632 | 23.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 22,500 | $50,550 | $19,787 | 39.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 35 | 187 | $87,799 | $18,612 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 128 | $66,317 | $16,821 | 25.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 118 | 477 | $15,111 | $4,912 | 32.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 138 | 589 | $13,730 | $4,458 | 32.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 85 | $18,981 | $4,157 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $14,638 | $3,658 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 51 | $13,418 | $3,349 | 25.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 130 | 353 | $8,197 | $2,932 | 35.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $11,127 | $2,770 | 24.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 33 | 104 | $11,211 | $2,334 | 20.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 39 | $14,286 | $1,958 | 13.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 18 | $6,114 | $1,671 | 27.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 49 | 106 | $4,334 | $1,416 | 32.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 25 | 117 | $11,454 | $1,413 | 12.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 20 | $4,597 | $1,234 | 26.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 53 | $7,871 | $1,168 | 14.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 20 | 52 | $2,621 | $855.92 | 32.7% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 11 | 6,840 | $2,075 | $774.21 | 37.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 13 | 105 | $20,700 | $752.84 | 3.6% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 16 | 5,250 | $16,853 | $680.81 | 4.0% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 38 | 98 | $1,776 | $566.12 | 31.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 50 | $3,685 | $521.23 | 14.1% |
| 83735 | Magnesium level | Office | 2023 | 17 | 70 | $1,407 | $459.90 | 32.7% |
About Dr. Janelle Meyer, MD
Dr. Janelle Meyer, MD is a Hematology & Oncology healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1881720068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Janelle Meyer, MD has received a total of $7,484 in payments from pharmaceutical and medical device companies, with $895.29 received in 2024. These payments were reported across 260 transactions from 62 companies. The most common payment nature is "Food and Beverage" ($4,849).
As a Medicare-enrolled provider, Meyer has provided services to 5,805 Medicare beneficiaries, totaling 132,466 services with total Medicare billing of $959,490. Data is available for 4 years (2020–2023), covering 136 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Internal Medicine
- Location Salem, OR
- Active Since 02/24/2007
- Last Updated 10/21/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1881720068
Products in Payments
- IMFINZI (Biological) $1,665
- IMBRUVICA (Drug) $281.25
- KEYTRUDA (Biological) $275.09
- DARZALEX (Biological) $152.13
- PROMACTA (Drug) $122.52
- Lenvima (Drug) $121.21
- TAGRISSO (Drug) $115.22
- OPDIVO (Biological) $112.97
- LYNPARZA (Drug) $103.77
- JAKAFI (Drug) $90.44
- IBRANCE (Drug) $88.94
- Xospata (Drug) $88.55
- LIBTAYO (Biological) $88.08
- ZEJULA (Drug) $84.99
- INLYTA (Drug) $73.52
- CABOMETYX (Drug) $69.38
- REBLOZYL (Biological) $66.43
- ERLEADA (Drug) $65.30
- Enhertu (Drug) $64.50
- Imbruvica (Drug) $63.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Salem
Igor Genkin, Md, MD
Hematology & Oncology — Payments: $37,121
Hematology & Oncology $37,121
Dr. Paul Richards, M.d, M.D
Hematology & Oncology — Payments: $29,258
Hematology & Oncology $29,258
Dr. Vandana Karri, Md, MD
Hematology & Oncology — Payments: $15,833
Hematology & Oncology $15,833
Dr. Mark Currie, M.d, M.D
Hematology & Oncology — Payments: $15,478
Hematology & Oncology $15,478
Dr. William Pierce, M.d, M.D
Hematology & Oncology — Payments: $9,460
Hematology & Oncology $9,460
John Strother, M.d, M.D
Hematology & Oncology — Payments: $3,216
Hematology & Oncology $3,216